Provenge
FDA Approves New Drug Xofigo for Advanced Prostate Cancer »
"The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for"...
Read the FDA Approves New Drug Xofigo for Advanced Prostate Cancer article »
Provenge
Provenge Consumer (continued)
OVERDOSE: If overdose is suspected, contact a poison control center or emergency room immediately. US residents can call the US National Poison Hotline at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: Do not share this medication with others.
It is very important to be on time to each of your appointments. This product has a short expiration period and must be used before it expires, or additional procedures will be needed to collect your white blood cells to prepare more sipuleucel-T.
MISSED DOSE: For the best possible benefit, it is important to receive each scheduled dose of this medication as directed. If you miss a dose, contact your doctor immediately to establish a new dosing schedule.
STORAGE: Not applicable. This medication is given in a hospital or clinic and will not be stored at home.
Information last revised December 2010. Copyright(c) 2010 First Databank, Inc.
Additional Provenge Information
Provenge - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Cancer
Get the latest treatment options.






